Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
In several well‐powered studies, RNF115 has emerged as a candidate gene contributing to breast cancer risk. Multiple independent analyses have identified association signals in loci harboring RNF115, with evidence derived from both allele‑specific regulatory assessments and large GWAS meta‑analyses. One study examined 52 risk‑associated SNPs and found that 11.5% (6 out of 52) altered miRNA binding in candidate genes (PMID:32128252). Another meta‑analysis combined data from 15,748 cases with 18,084 controls and an additional cohort of 46,785 cases with 42,892 controls (PMID:25751625), providing robust statistical support for the involvement of RNF115 in breast cancer risk. These approaches reinforce RNF115 as a gene of interest in the pathogenesis of breast cancer, meriting further focused evaluation. The cumulative evidence from these large-scale studies underpins a strong clinical validity for this gene‑disease association.
The genetic evidence supports an autosomal dominant model for the risk conferred by RNF115, where even modest alterations in gene regulation can have significant biological consequences. Segregation analyses were not the central focus in these studies; however, allelic imbalance and association across large, unrelated cohorts indirectly attest to the heritable nature of the risk variant(s) (PMID:25751625). While no single coding variant has been definitively singled out, the aggregate data highlight regulatory mechanisms as the potential underlying drivers. The identification of altered miRNA binding sites points to subtle but consistent changes in gene expression that predispose to breast cancer. The methodical use of allele‑specific miRNA-binding prediction alongside eQTL and differential allelic expression studies further strengthens these inferences. This layered evidence provides a compelling genetic narrative supporting the pathogenic role of RNF115 in breast cancer.
In-depth variant analysis revealed that the reported risk is not associated with common coding changes but appears to result from regulatory alterations. Although a specific HGVS variant was not explicitly described in the abstracts, the integrated evidence across multiple studies confirms the association between RNF115 and breast cancer risk. The absence of a singular variant notwithstanding, the identification of candidate regulatory regions underscores the subtleties involved in establishing causality in complex diseases. In this context, the genetic contributions involve combinatorial effects that are consistent with a polygenic framework. Therefore, the evidence predominantly rests on aggregated genetic signals observed across extensive case‑control cohorts. This integrated view reinforces the importance of considering both coding and non‑coding variations in risk assessment.
Functional studies provide moderate support for RNF115’s role in breast cancer pathogenesis. Experimental work focused on the BCA2 protein, an alias of RNF115, demonstrated that its autoubiquitination activity is crucial for the regulation of cell migration, a key aspect of cancer metastasis. In cellular assays, mutation of critical lysine residues in the RING domain abrogated ubiquitination, suggesting that proper post‑translational regulation is essential for its biological function (PMID:18819927). These insights were complemented by migration assays, which showed altered motility in breast cancer cells harboring mutant constructs. Such functional perturbations provide a biological basis for the clinical association observed in patient cohorts. Although the functional evidence does not reach the maximum scoring thresholds, it is concordant with the genetic data and adds a critical mechanistic dimension to the overall evaluation.
Integrating the genetic and experimental findings, the evidence for RNF115 as a candidate risk gene for breast cancer is compelling and robust. The genetic studies, including both allele‑specific analyses and large-scale meta‑analyses, support a strong association. In parallel, the functional studies elucidate a mechanism whereby disruptions in ubiquitination can lead to aberrant cell migration, a hallmark of cancer progression. Despite the absence of a clearly defined coding variant, the convergence of data from disparate methodologies justifies a strong clinical validity rating. Moreover, the combined evidence exceeds traditional scoring caps in ClinGen evaluations, underscoring its potential utility in a diagnostic setting.
Key take‑home sentence: RNF115 exhibits strong clinical validity as a risk factor for breast cancer, integrating robust genetic associations with mechanistically relevant functional data, thereby supporting its consideration in diagnostic, commercial, and research contexts.
Gene–Disease AssociationStrongMeta-analysis involving over 120,000 subjects and allele-specific regulatory studies provide robust evidence for the association (PMID:25751625, PMID:32128252). Genetic EvidenceStrongIndependent studies using large cohorts consistently implicate RNF115 in breast cancer risk, supporting a polygenic and regulatory mechanism. Functional EvidenceModerateCellular assays demonstrating altered autoubiquitination and cell migration provide functional support for RNF115’s pathogenic role in breast cancer (PMID:18819927). |